NephroGenex pharmaceutical company focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. Learn more about our work in exploring the unique promise against the fundamental causes of unmet medical needs.
http://nephrogenex.investorhq.businesswire.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
3.3 seconds
PAGES IN
THIS WEBSITE
18
SSL
EXTERNAL LINKS
19
SITE IP
204.8.173.159
LOAD TIME
3.266 sec
SCORE
6.2
NephroGenex Investor Center - Innovative Therapies for Kidney Disease | | nephrogenex.investorhq.businesswire.com Reviews
https://nephrogenex.investorhq.businesswire.com
NephroGenex pharmaceutical company focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. Learn more about our work in exploring the unique promise against the fundamental causes of unmet medical needs.
nephrogenex.investorhq.businesswire.com
Analyst Coverage | NephroGenex Investor Center - Innovative Therapies for Kidney Disease
http://nephrogenex.investorhq.businesswire.com/analyst-coverage
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Annual Reports and Proxies. NephroGenex is covered by the following analysts. HC Wainwright and Co. Publications & Abstracts. PIONEER Phase 3 Program. Events & Presentations. Annual Reports & Proxies.
SEC Filings | NephroGenex Investor Center - Innovative Therapies for Kidney Disease
http://nephrogenex.investorhq.businesswire.com/sec-filings
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Events & Presentations. Annual Reports & Proxies. PYRIDORIN (pyridoxamine dihydrochloride) is a registered trademark of NephroGenex, Inc.
all Press Releases | NephroGenex Investor Center - Innovative Therapies for Kidney Disease
http://nephrogenex.investorhq.businesswire.com/press-releases/all/all/all
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Annual Reports and Proxies. NephroGenex, Inc. Commences Voluntary Chapter 11 Proceeding; Seeks To Initiate Sale Process Under Section 363. 5/2/16 8:00 am EDT. RALEIGH, N.C.- ( BUSINESS WIRE. NephroGenex Provides Corporate Update. 2/24/16 9:20 am EST. NephroGenex to Presen...
Historical Stock Lookup | NephroGenex Investor Center - Innovative Therapies for Kidney Disease
http://nephrogenex.investorhq.businesswire.com/stock-chart/historical-stock-lookup
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Events & Presentations. Annual Reports & Proxies. PYRIDORIN (pyridoxamine dihydrochloride) is a registered trademark of NephroGenex, Inc.
Corporate Governance | NephroGenex Investor Center - Innovative Therapies for Kidney Disease
http://nephrogenex.investorhq.businesswire.com/corporate-governance
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Annual Reports and Proxies. Nominating and Governance Committee Charter. Corporate Code of Conduct and Ethics and Whistleblower Policy. Publications & Abstracts. PIONEER Phase 3 Program. Events & Presentations. Annual Reports & Proxies.
TOTAL PAGES IN THIS WEBSITE
18
Board of Directors - NephroGenex, Inc.
http://www.nephrogenex.com/about-us/board-directors
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Richard J. Markham. Richard J. Markham has been Chairman of the Board of Directors since October, and a member since 2007. Mr. Markham is also a partner at the venture capital firm Care Capital, LLC. Prior to joining Care Capital in 2004, he was the Vice Chairman of the Management Board and COO of Aventis. Mr Markham received ...
What is Chronic Kidney Disease?
http://www.nephrogenex.com/kidney-disease
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Chronic Kidney Disease Affects Over One-Third of Diabetics in the U.S. Patients with long-standing diabetes are at high risk for developing renal failure. Hypertension, uncontrolled blood sugar may pose irreversible kidney damage. Some common, and even early, indications of CKD are:. Muscle cramping at night. Dry, itchy skin.
Diabetic Nephropathy: A Chronic Complication of Diabetes
http://www.nephrogenex.com/kidney-disease/diabetic-nephropathy
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Diabetic Nephropathy: A Chronic, Life-Threatening Complication of Diabetes. Within the bloodstream, the excessively high glucose reacts with proteins to form unstable compounds known as Schiff bases which are rapidly converted to more stable compounds known as Amadori products. These Amadori products are in-turn converted ...
Earlier clinical studies with Pyridorin
http://www.nephrogenex.com/clinical-trials/previous-pyridorin-clinical-studies
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. PIONEER Phase 3 Program. Early Studies Show Clinical Benefit for Target Patient Population. Pyridorin well tolerated, with adverse event rates similar to placebo. Following several preclinical and Phase 1 studies, four placebo-controlled PYRIDORIN. PYR-206 was a Phase 2, multi-center, placebo-controlled, randomized, double-bli...
What is Acute Kidney Injury?
http://www.nephrogenex.com/kidney-disease/acute-kidney-injury
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Many Critical Care Patients Are at Risk for Acute Kidney Injury. The condition can result in loss of kidney function in just 1-2 days. AKI is a serious condition that is estimated to affect between 7 and 18 percent of hospital inpatients. Major causes of acute kidney injury include:. The prognosis for AKI depends on the severi...
Pyridorin: Treatment in development for diabetic nephropathy
http://www.nephrogenex.com/product-candidates/pyridorin
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. Pyridorin: A Novel Acting Compound to Improve Treatment of Diabetic Nephropathy. Addressing an unmet medical need to slow disease progression. Currently available treatments for diabetic nephropathy are effective but a significant residual risk remains. Unlike any currently approved therapies, Pyridor...
Pipeline - NephroGenex, Inc.
http://www.nephrogenex.com/clinical-trials/pipeline
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. PIONEER Phase 3 Program. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Events & Presentations. Annual Reports & Proxies. PYRIDORIN (pyridoxamine dihydrochloride) is a registered trademark of NephroGenex, Inc.
Publications & Abstracts - NephroGenex, Inc.
http://www.nephrogenex.com/product-candidates/publications-abstracts
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. Publications & Abstracts. Clinical and Preclinical Activities of PYRIDORIN. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, Striker LJ, Striker GE. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int. 70:507-...Kakuta T,...
Management Team - NephroGenex, Inc.
http://www.nephrogenex.com/about-us/management-team
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. John P. Hamill. Chief Executive Officer and Chief Financial Officer. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Events & Presentations. Annual Reports & Proxies. PYRIDORIN (pyridoxamine dihydrochloride) is a registered trademark of NephroGenex, Inc.
NephroGenex - Innovation in the treatment of Kidney Disease
http://www.nephrogenexinc.com/about-us
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. NephroGenex is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. We have been pioneering the development of PYRIDORIN. We believe Pyridorin represents real hope for the millions of type 2 diabetic patients around the world who have diabetic nephropathy.
TOTAL LINKS TO THIS WEBSITE
19
Register Diabetische Nephropathie - Med. Klinik m.S. Nephrologie und Internistische Intensivmedizin, Charité-Universitätsmedizin Berlin
Patienten / Angehörige. Herzlich willkommen auf unserer Webseite. Wir freuen uns, Ihnen hier eine neue Studie vorstellen zu können. Mit dem 'Register Diabetische Nephropathie' wollen wir unbekannte genetische Ursachen der Diabetes-Mellitus-bedingten Nierenschädigung und neue diagnostische und therapeutische Optionen identifizieren. Sollten wir Ihr Interesse an einer Studienteilnahme als Patient. Geweckt haben oder Sie als ärztlicher Kollege. Univ-Prof. Dr. med. Maik Gollasch (Studienleiter).
Naše doména nephrogenetics.com parkuje u CZECHIA.COM
420 603 196 637. Je parkována u CZECHIA.COM. Ceny jsou uvedeny bez DPH a platí na první rok registrace. Důvěryhodné SSL certifikáty pro zabezpečení webu a aplikací. Plně důvěryhodný RapidSSL od 395 Kč ročně ochrání vaše zákazníky před odposlechem. Naši specialisté vám pomohou co nejlépe zabezpečit váš web, server nebo aplikaci. Translate('Nainstalujeme vám zdarma Open Source aplikace! Nainstalujeme vám zdarma Open Source aplikace! Revoluční šablona inPage One. Vaše účetnictví v bezpečí. Díky pečlivě navr...
nephrogenetics.hacettepe.edu.tr
Hacettepe Üniversitesi Pediatri Nefroloji Ünitesi Nefrogenetik Laboratuvarı
Önemlidir.Kan Göndermeden Önce Mutlaka Okuyunuz. Genetik Çalışmalar İçin Materyal Gönderirken. Materyali göndermeden önce Doç. Dr. Fatih Özaltın ile irtibat kurulması gerekmektedir. Web tabanlı aHUS Kayıt Sistemi: http:/ ahusnet.org. Sisteme ilk kez hasta girecek merkezlerin yeni kayıt formunu ( http:/ ahusnet.org/yeni-uyelik.php. 650 aileden 1500 ün üzerinde DNA ile steroide dirençli nefrotik sendrom fenotipi ile ilgili çok geniş bir veri ve DNA arşivi oluşturulmuştur. Bunlara Türkiye deki farklı ne...
Workshop 03.12.2015
Workshop 03.12.2015. Sehr geehrte Kolleginnen und Kollegen,. Es ist uns eine besondere Freude, Sie hiermit zu dem nun inzwischen dritten Nephrogenetik Workshop einzuladen. Wie im letzten Jahr findet diese Veranstaltung wieder am Vortag des Berliner Apherese-/Dialyseseminars statt. Diese Konsequenzen erwachsen aus dem Fortschritt auf drei verschiedenen Gebieten:. 1) Bessere Möglichkeiten der genetischen Diagnostik. Die neue Möglichkeiten. 2) Grundlagenforschung. Ständig werden neue Gene als krankheits...
nephrogenex.investorhq.businesswire.com
NephroGenex Investor Center - Innovative Therapies for Kidney Disease |
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Annual Reports and Proxies. Annual Reports and Proxies. 8/12/15 4:12 pm EDT. NephroGenex Reports Second Quarter 2015 Financial Results. 8/6/15 4:05 pm EDT. NephroGenex To Host Conference Call and Webcast on Second Quarter 2015 Financial Results on Thursday, August 13, 2015. Q1 2015 Quarterly Results.
Home - NephroGenex, Inc.
Innovative Therapies for Kidney Disease. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Publications & Abstracts. PIONEER Phase 3 Program. Investors & Media. Treating an underlying cause of diabetic kidney disease. Aiming to slow progression of the disease in 6 million patients at risk of kidney failure. Now enrolling pivotal Phase 3 PIONEER study in diabetic nephropathy. In Diabetic Nephropathy" alt="PYRIDORIN. In Diabetic Nephropathy" /. In Diabetic Nephropathy" PYRIDORIN. RALEIG...
nephrogenic-diabetes-insipidus.blogspot.com
nephrogenic diabetes insipidus symptoms
Nephrogenic Diabetes Insipidus and Symptoms. Nephrogenic Diabetes Insipidus and Symptoms. Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Sunday, April 1, 2012. Keywords : nephrogenic diabetes insipidus. By :Veronika Kirchlechner, Dieter Y Koller, Reiner Seidl, Franz Waldhauser. Treatment of nephrogenic diabetes insipidus. Focuses on the reduction of polyuria to avoid dehydration and hypernatraemia and therefore on prevention of early. 6 by which a reduction of the.
nephrogenic.com - Registered at Namecheap.com
This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! The Sponsored Listings displayed above are served automatically by a third party. Neither Parkingcrew nor the domain owner maintain any relationship with the advertisers.
nephrogenicfibrosingdermopathy.org
Nephrogenicfibrosingdermopathy.org
nephrogenicsystemicfibrosis.net
Nephrogenicsystemicfibrosis.net
SOCIAL ENGAGEMENT